Skip to product information
1 of 1

Invivo Anti-Mouse CD366 (TIM-3) Recombinant mAb

Invivo Anti-Mouse CD366 (TIM-3) Recombinant mAb

Catalog Number: S0B1073 Application: ELISA,WB,FCM,Functional/Block/Neutralize Reactivity: Mouse Conjugation: Unconjugated Brand: Starter
Price:
Regular price $120.00 USD
Regular price Sale price $120.00 USD
Size:
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Host Rat
Antigen CD366
Synonyms Hepatitis A virus cellular receptor 2 homolog, HAVcr-2, T-cell immunoglobulin and mucin domain-containing protein 3 (TIMD-3), T-cell immunoglobulin mucin receptor 3 (TIM-3), T-cell membrane protein 3, Timd3
Location Membrane
Accession Q8VIM0
Clone Number S-R478-1
Antibody Type Rat mAb
Isotype Rat IgG2a,k
Isotype Control Invivo rat IgG2a isotype control
Application ELISA, WB, FCM, in vivo TIM-3 neutralization, in vitro TIM-3 blocking
Reactivity Ms
Purification Protein G
Concentration 5 mg/ml
Endotoxin <2EU/mg
Conjugation Unconjugated
Physical Appearance Liquid
Storage Buffer

PBS pH7.4, containing no preservative

Stability & Storage

2 to 8 °C for 2 weeks under sterile conditions;

-20 °C for 3 months under sterile conditions; 

-80 °C for 24 months under sterile conditions.

Please avoid repeated freeze-thaw cycles.

Dilution


application dilution species
WB 1:1000 Ms

Background

TIM-3 (T cell immunoglobulin and mucin domain-containing protein 3), also known as HAVCR2, is a crucial immune checkpoint molecule that is extensively expressed on various immune cells, including Th1, Th17, Treg, dendritic cells, monocytes, macrophages, and NK cells. The role of TIM-3 in the tumor immune microenvironment is particularly significant, as it is highly expressed on tumor-infiltrating CD8+ T cells and regulatory T cells (Tregs), and is co-expressed with PD-1, participating in the regulation of tumor immune evasion and T cell exhaustion. TIM-3 exerts its immune suppressive function by binding to its ligands, which include galectin-9 (Gal-9), phosphatidylserine (PtdSer), carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1), and high mobility group box 1 (HMGB1). These interactions lead to Th1 cell apoptosis, T cell exhaustion, and immune suppression, thereby facilitating tumor cells to evade immune surveillance. In cancer treatment strategies, TIM-3 has emerged as a promising target. Furthermore, the expression level of TIM-3 correlates with poor prognosis in certain types of cancer, making it a potential prognostic biomarker.

Picture

Western Blot

WB result of Invivo Anti-Mouse CD366 (TIM-3) Recombinant mAb
Primary antibody: Invivo Anti-Mouse CD366 (TIM-3) Recombinant mAb at 1/1000 dilution
Lane 1: TIM-3/HAVCR2 His Tag Protein, Mouse 2 μg
Lane 2: TIM-3/HAVCR2 His Tag Protein, Human 2 μg
Secondary antibody: Goat Anti-rat IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 33~55 kDa
Observed MW: 33~50 kDa
This blot was developed with high sensitivity substrate

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)